EUVIMEDEUVIMED entdecken
Crossref

Design and Synthesis of Edaravone Derivatives Containing 6‐(4‐aminophenyl)‐4,5‐dihydropyridazin‐3(2 H )‐one as Bifunctional Anti‐ischemic Stroke Agents

Yi Li iD, Ting Cai, Yong Li, Lingling Fan, Lei Tang

Chemistry & Biodiversity · 2025

DOI: 10.1002/cbdv.202500516 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemistry & Biodiversity, 2025. Verfasst von Yi Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine & School of Pharmaceutical Sciences, Guizh…. Hauptthemen laut MEDLINE: Edaravone, Drug Design, Platelet Aggregation Inhibitors, Neuroprotective Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ischemic stroke gravely endangers human health. To develop novel drugs with antiplatelet and neuroprotective functions for ischemic stroke, edaravone derivatives CT01–CT20 , containing 6‐(4‐aminophenyl)‐4,5‐dihydropyridazin‐3(2 H )‐one, were synthesized from materials like dimethyl butynedioate, ethyl acetoacetate, and diethyl 1,3‐acetonedicarboxylate, via cyclization, hydrolysis, and condensation. Among them, CT16 exhibited outstanding antiplatelet activity (IC 50 = 6.72 µM), absent in edaravone. It also surpassed edaravone in 1,1‐diphenyl‐2‐picrylhydrazyl radical scavenging (EC 50 = 30.80 µM) and protecting PC12 cells from H₂O₂ damage. In vivo, CT16 effectively reduced carotid artery thrombosis in rats and enhanced blood flow. In the middle cerebral artery occlusion reperfusion injury model, it shrank infarct size, improved neurological scores, increased cerebral blood flow, and lessened brain edema. Preliminary safety tests indicated CT16 didn't alter rat blood biochemistry or organ pathology, with a low bleeding risk as an antiplatelet agent. Molecular docking suggested it may inhibit phosphodiesterase 3A to achieve an antiplatelet effect. In conclusion, CT16 has both antiplatelet aggregation and neuroprotective effects and is a potential candidate compound for the treatment of ischemic stroke.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EdaravoneDrug DesignPlatelet Aggregation InhibitorsNeuroprotective AgentsIschemic StrokeAnimalsRatsPC12 CellsMaleStructure-Activity RelationshipRats, Sprague-DawleyMolecular StructureMolecular Docking SimulationDose-Response Relationship, DrugHydrogen PeroxidePlatelet Aggregation

Stichwörter der Autor:innen

6‐(4‐aminophenyl)‐4,5‐dihydropyridazin‐3(2H)‐oneEdaravoneanti‐platelet aggregationischemic strokeneuroprotective

Substanzen

EdaravonePlatelet Aggregation InhibitorsNeuroprotective AgentsHydrogen Peroxide

Autor:innen und Institutionen

  • State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine & School of Pharmaceutical Sciences, Guizhou Medical University, Guiyang, China.

ORCID-Profile: Yi Li

Zitieren

APA

Li, Y., Cai, T., Li, Y., Fan, L., & Tang, L. (2025). Design and Synthesis of Edaravone Derivatives Containing 6‐(4‐aminophenyl)‐4,5‐dihydropyridazin‐3(2 H )‐one as Bifunctional Anti‐ischemic Stroke Agents. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.202500516

Vancouver

Li Y, Cai T, Li Y, Fan L, Tang L. Design and Synthesis of Edaravone Derivatives Containing 6‐(4‐aminophenyl)‐4,5‐dihydropyridazin‐3(2 H )‐one as Bifunctional Anti‐ischemic Stroke Agents. Chemistry & Biodiversity. 2025. doi:10.1002/cbdv.202500516

BibTeX
@article{Li2025,
  author = {Li, Yi and Cai, Ting and Li, Yong and Fan, Lingling and Tang, Lei},
  title = {Design and Synthesis of Edaravone Derivatives Containing 6‐(4‐aminophenyl)‐4,5‐dihydropyridazin‐3(2 H )‐one as Bifunctional Anti‐ischemic Stroke Agents},
  journal = {Chemistry & Biodiversity},
  year = {2025},
  doi = {10.1002/cbdv.202500516}
}
Kostenlos starten →